Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.85 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.76 |
| ▸ | PTGIR | P43119 | 1/20 | 0.69 |
| ▸ | CHKA | P35790 | 1/20 | 0.68 |
| ▸ | POLB | P06746 | 2/20 | 0.62 |
| ▸ | PKM | P14618 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | HTR1A | P08908 | 1/20 | 0.59 |
| ▸ | DRD2 | P14416 | 1/20 | 0.59 |
| ▸ | HTR2B | P41595 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20804352 | 1.00 | SIGMAR1 (0.85) | SIGMAR1SMN1; SMN2PTGIRCHKAPOLB | |
| SCHEMBL19285228 | 1.00 | SIGMAR1 (0.85) | SIGMAR1SMN1; SMN2PTGIRCHKAPOLB | |
| SCHEMBL1045386 | 0.94 | SIGMAR1 (0.77) | SIGMAR1SMN1; SMN2PTGIRCHKAPOLB | |
| SCHEMBL1043090 | 0.94 | SIGMAR1 (0.77) | SIGMAR1SMN1; SMN2PTGIRCHKAPOLB | |
| SCHEMBL22642319 | 0.92 | SIGMAR1 (0.74) | SIGMAR1SMN1; SMN2PTGIRCHKAPOLB | |
| SCHEMBL12126812 | 0.92 | CHKA (0.79) | SIGMAR1SMN1; SMN2PTGIRCHKAPOLB | |
| SCHEMBL18234102 | 0.92 | SIGMAR1 (0.74) | SIGMAR1SMN1; SMN2PTGIRCHKAPOLB | |
| SCHEMBL3171551 | 0.92 | PTGIR (0.81) | SIGMAR1SMN1; SMN2PTGIRCHKAALDH1A1 | |
| SCHEMBL1045927 | 0.92 | PTGIR (0.75) | SIGMAR1SMN1; SMN2PTGIRCHKAPOLB | |
| SCHEMBL10502107 | 0.91 | SIGMAR1 (0.72) | SIGMAR1SMN1; SMN2PTGIRCHKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2269995-B1 | PROCESS FOR PRODUCTION OF POLYMERS WITH IRON COMPLEX CATALYST | DAINIPPON INK & CHEMICALS (JP) | 2012-12-12 | — | — | EP | disclosed |
| US-8017706-B2 | Process for production of polymers with iron complex catalyst | DIC CORPORATION (JP) | 2011-09-13 | — | — | US | disclosed |
| US-20110105703-A1 | PROCESS FOR PRODUCTION OF POLYMERS WITH IRON COMPLEX CATALYST | DIC Corporatio (JP) | 2011-05-05 | — | — | US | disclosed |
| EP-2269995-A1 | PROCESS FOR PRODUCTION OF POLYMERS WITH IRON COMPLEX CATALYST | DIC Corporation (JP) | 2011-01-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105703-A1 | PROCESS FOR PRODUCTION OF POLYMERS WITH IRON COMPLEX CATALYST | TFRC, FECH, FTH1 | SIGMAR1 886/4885SMN1; SMN2 3504/4885PTGIR 504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.